All In Biotech

Drug Trial Radar · NCT07647107

A Phase I Study of Lipovaxin Tuberculosis Vaccine in Adult Healthy Populations

A Phase I, Double-Blind, Randomized, Placebo Controlled Trial to Evaluate Safety and Immunogenicity of Lipovaxin Tuberculosis Vaccine (Bio Farma) in Healthy Populations Aged 18-40 Years in Indonesia

Last checked: Nov 20, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

60

Planned (sponsor's estimate)

Start

Sep 8, 2026

Primary completion

Jul 2027

Study completion Aug 2027

Sponsor

Lead sponsor
PT Bio FarmaIndustry
Sponsor type
Industry
Collaborators
Fakultas Kedokteran Universitas Indonesia; Dr Cipto Mangunkusumo General Hospital
First posted
Jun 15, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Sequential
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 40 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

A Phase I, Double-Blind, Randomized, Placebo Controlled Trial to Evaluate Safety and Immunogenicity of Lipovaxin Tuberculosis Vaccine (Bio Farma) in Healthy Populations Aged 18-40 Years in Indonesia

Conditions

  • Tuberculosis
  • TB Infection

Interventions

  • LipovaxinS4-EAH (Middle Dose)Biological

    0,5 mL of Middle Dose LipovaxinS4-EAH. Administered twice, 28 days apart

  • LipovaksinS4-EAH (High Dose)Biological

    0,5 mL of HIgh Dose LipovaxinS4-EAH. Administered twice, 28 days apart

  • PlaceboBiological

    0,5 mL of Placebo containing NaCl 0.9%. Administered twice, 28 days apart

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Local and systemic reactionsTime frame: 30 minutes, 7 days and 28 days after 1st injection and 2nd injection for all group, and 30 minutes, 7 days and 28 days after 1st injection and 2nd injection and 14 days after 1st dose for sentinel group
  2. Any AEs and SAEsTime frame: until 6 months after 2nd injection
  3. Laboratory changesTime frame: D0, 14 days after 1st injection (sentinel), 28 days after 2nd injection

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Cipto Mangunkusumo Hospital, Jl. Pangeran Diponegoro No. 71, Kenari, Jakarta Pusat, DKI Jakarta.

    Jakarta Pusat, DKI Jakarta, Indonesia · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.